Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen Gets Parsabiv CRL, Gives No Clues As To Why

Executive Summary

FDA issued a complete response letter for the Sensipar follow-on, and Amgen declined to provide any details about the reason why or timeline for resubmission.


Related Content

Parsabiv Could Allow Amgen To Maintain Control Of Calcimimetics Market
Amgen's Parsabiv Approved With Unusual Postmarketing Requirements
Amgen's Parsabiv's Gets EU Approval While It Languishes At The FDA
3Q Pharma Results Preview: Novartis, Merck, Lilly, Bayer, GSK, Bristol, Amgen, Sanofi
Keeping Track: Amgen Parsabiv Is Latest To Receive Complete Response; Pfizer Troxyca ER Finally Approved; Remune Returns
Amgen's Reticence On Parsabiv Complete Response Letter Revives Transparency Issue
Amgen Files NDA For I.V. Rival To Sensipar
Amgen Planned Acquisition Of KAI Would Bring In Replacement For Sensipar


Related Companies